Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 9, Number 12—December 2003
Dispatch

Visceral Leishmaniasis Treatment, Italy

Luigi Gradoni*Comments to Author , Marina Gramiccia*, and Aldo Scalone*
Author affiliations: *Istituto Superiore di Sanità, Rome, Italy

Main Article

Figure 2

Annual proportion of immunocompetent patients with visceral leishmaniasis treated with meglumine antimoniate (MA) or amphotericin B (AmB) in the period 1995–2001.

Figure 2. Annual proportion of immunocompetent patients with visceral leishmaniasis treated with meglumine antimoniate (MA) or amphotericin B (AmB) in the period 1995–2001.

Main Article

Page created: February 08, 2011
Page updated: February 08, 2011
Page reviewed: February 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external